Following similar work by Canadian researchers in E. coli, the study indicates interest in LC-MS/MS in clinical microbiology, which has been dominated by MALDI.
The company reported revenues of $375.4 million, up from $353.5 million for the first quarter of 2015 and above analysts' consensus estimate of $360.2 million.
The investment bank said it expects that continued margin expansion will be more challenging than the company's stock price indicates.
The approach allows more rapid detection of resistant strains as well as detection of certain populations for which good clinical assays don't currently exist.
The company reported Q4 revenues of $478.2 million and organic revenue growth of nearly 3 percent as currency effects negatively impacted revenues by 8 percent.
While much attention has focused on triple quads, MALDI-TOFs offer advantages in simplicity and throughput that could help them make clinical inroads.
The investment bank also initiated coverage of Agilent Technologies, Bruker, Illumina, PerkinElmer, and Waters with a Hold rating.
There were more winners than losers in the 2015 GWDN Index, but some lost big.
Their approach detects resistance to carbapenems, drugs commonly used in hospitals and in patients with infections already resistant to other antibiotics.
The program will run for two years, and Bruker said that it will repurchase its common stock from time to time in amounts and at prices that it deems appropriate.
An international commission is to develop a report on how researchers, clinicians, and regulators should evaluate the clinical applications of human germline genome editing.
The American Prospect writes that the pilot program to test the DNA of migrants could lead to more family separations.
The US Department of Agriculture presents a new blueprint for animal genomic research.
In Genome Research this week: repetitive element deletion linked to altered methylation and more in form of muscular dystrophy; human contamination in draft bacterial and archaeal genomes; and more.